Company intelligence / Profile preview

bioTheranostics, Inc.

San Diego, California, United Statesbreastcancerindex.com ↗

Ownership: Public · HOLX
Development stage: Commercial

Overview

Biotheranostics provides molecular diagnostic tests for cancer patients, including Breast Cancer Index (BCI) for breast cancer prognosis and CancerTYPE ID for tumor site of origin determination. Both tests are PCR-based gene expression tests that have been extensively validated and are widely reimbursed in the United States.

Therapeutic areas: Oncology
Modalities: Molecular diagnostic testsPCR-based gene expression tests
Industry: Molecular Diagnostics

Drug pipeline

2 assets

Breast Cancer Index

Commercial

Indications: Breast cancer

1 more asset in the full pipeline.

Request access →

Financials

Market cap: $17B
Total revenue: $1B
Enterprise value: $17.1B

Beyond the preview

Go deeper on bioTheranostics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bioTheranostics, Inc..

Explore the full profile